Literature DB >> 11428978

Antiviral drug resistance in human cytomegalovirus.

S Chou1.   

Abstract

Drug-resistant cytomegalovirus (CMV) should be considered when viral shedding persists after several weeks of therapy. The problem is most likely to arise in the setting of a severely immunosuppressed host with continuing or relapsing disease. Not all treatment failure can be attributed to drug resistance. The testing of CMV isolates for drug resistance in cell culture is time-consuming and labor-intensive, but recent advances in understanding of the genetics of resistance have resulted in rapid genotypic assays for specific mutations in the viral UL97 phosphotransferase or UL54 DNA polymerase genes that can predict resistance and cross-resistance to specific drugs. This information may help in the selection of alternative therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 11428978     DOI: 10.1034/j.1399-3062.1999.010204.x

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  23 in total

1.  A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir.

Authors:  S Chou; C L Meichsner
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

2.  Use of time-saving flow cytometry for rapid determination of resistance of human cytomegalovirus to ganciclovir.

Authors:  Gyu-Cheol Lee; Dong-Gun Lee; Su-Mi Choi; Jin-Hong Yoo; Sun-Hee Park; Jung-Hyun Choi; Woo-Sung Min; Ok-Hee Cho; Chan-Hee Lee; Wan-Shik Shin
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Detection of Two Drug-Resistance Mutants of the Cytomegalovirus by High-Resolution Melting Analysis.

Authors:  Xiao-Fan Chen; Tian-Run Li; Hong Yang; Yong Shao; Jie Zhang; Wei Zhang; Bo Yu; Zhun Wei; Bo Wu; Lin Yu
Journal:  J Clin Lab Anal       Date:  2015-05-13       Impact factor: 2.352

4.  Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.

Authors:  Gillian M Scott; Adriana Weinberg; William D Rawlinson; Sunwen Chou
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

5.  Fatal reactivation of postnatal cytomegalovirus infection with rapid emergence of ganciclovir resistance in an infant after allogeneic stem cell transplantation.

Authors:  Sebastian Voigt; Detlef Michel; Olivia Kershaw; Jörn-Sven Kühl; Thomas Mertens; Wolfram Ebell; Helga Meisel
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

6.  The non-nucleoside antiviral, BAY 38-4766, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs.

Authors:  Mark R Schleiss; David I Bernstein; Michael A McVoy; Greg Stroup; Fernando Bravo; Blaine Creasy; Alistair McGregor; Kristin Henninger; Sabine Hallenberger
Journal:  Antiviral Res       Date:  2005-01       Impact factor: 5.970

7.  Sequencing of cytomegalovirus UL97 gene for genotypic antiviral resistance testing.

Authors:  N S Lurain; A Weinberg; C S Crumpacker; S Chou
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 8.  CNS manifestations of cytomegalovirus infections: diagnosis and treatment.

Authors:  Matthias Maschke; Oliver Kastrup; Hans-Christoph Diener
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

9.  Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication.

Authors:  George W Koszalka; Nelson W Johnson; Steven S Good; Leslie Boyd; Stanley C Chamberlain; Leroy B Townsend; John C Drach; Karen K Biron
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers.

Authors:  Ravit Arav-Boger; Ran He; Chuang-Jiun Chiou; Jianyong Liu; Lauren Woodard; Andrew Rosenthal; Lorraine Jones-Brando; Michael Forman; Gary Posner
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.